Acquavella J, Mehra R, Bron M, et al. Prevalence of narcolepsy and other sleep disorders and frequency of diagnostic tests from 2013–2016 in insured patients actively seeking care. J Clin Sleep Med. 2020;16:1255–63.

Article  PubMed  PubMed Central  Google Scholar 

Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy-clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15:519–39.

Article  PubMed  Google Scholar 

Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep. 2007;30:13–26.

Article  PubMed  Google Scholar 

Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100.

Article  PubMed  Google Scholar 

Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13:419–25.

Article  PubMed  PubMed Central  Google Scholar 

Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20:83–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654–62.

Article  CAS  PubMed  Google Scholar 

Xie X, Crowder TL, Yamanaka A, et al. GABA(B) receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus. J Physiol. 2006;574:399–414.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Felmlee MA, Morse BL, Morris ME. Gamma-hydroxybutyric acid: pharmacokinetics, pharmacodynamics, and toxicology. AAPS J. 2021;23:22.

Article  CAS  PubMed  Google Scholar 

Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6:1–6.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration Center for Drug Evaluation and Research. NDA 21-196 Xyrem (sodium oxybate) oral solution approval letter. Rockville: US Food and Drug Administration; 2002.

US Food & Drug Administration. Memorandum: Decision to waive the requirement for a single, shared system REMS for sodium oxybate oral solution. 2017. https://www.fda.gov/media/102913/download. Accessed 16 Oct 2024.

White CM. Pharmacologic, pharmacokinetic, and clinical assessment of illicitly used gamma-hydroxybutyrate. J Clin Pharmacol. 2017;57:33–9.

Article  CAS  PubMed  Google Scholar 

Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3:433–51.

Article  CAS  PubMed  Google Scholar 

Helrich M, McAslan TC, Skolnik S, Bessman SP. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology. 1964;25:771–5.

Article  CAS  PubMed  Google Scholar 

Blumenfeld M, Suntay RG, Harmel MH. Sodium gamma-hydroxybutyric acid: a new anesthetic adjuvant. Anesth Analg. 1962;41:721–6.

Article  Google Scholar 

Vickers MD. Gammahydroxybutyric acid. Int Anesthesiol Clin. 1969;7:75–89.

Article  CAS  PubMed  Google Scholar 

Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008;10:311–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carai MA, Colombo G, Brunetti G, et al. Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. Eur J Pharmacol. 2001;428:315–21.

Article  CAS  PubMed  Google Scholar 

Carai MA, Lobina C, Maccioni P, et al. Gamma-aminobutyric acidB (GABAB)-receptor mediation of different in vivo effects of gamma-butyrolactone. J Pharmacol Sci. 2008;106:199–207.

Article  CAS  PubMed  Google Scholar 

Kaupmann K, Cryan JF, Wellendorph P, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci. 2003;18:2722–30.

Article  PubMed  Google Scholar 

Morse BL, Vijay N, Morris ME. gamma-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol. 2012;82:226–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Absalom N, Eghorn LF, Villumsen IS, et al. alpha4betadelta GABA(A) receptors are high-affinity targets for gamma-hydroxybutyric acid (GHB). Proc Natl Acad Sci USA. 2012;109:13404–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benavides J, Rumigny J, Bourguignon J, et al. High affinity binding site for γ-hydroxybutyric acid in rat brain. Life Sci. 1982;30:953–61.

Article  CAS  PubMed  Google Scholar 

Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci. 1980;7:23–31.

CAS  PubMed  Google Scholar 

Montplaisir J, Godbout R. Nocturnal sleep of narcoleptic patients: revisited. Sleep. 1986;9:159–61.

Article  CAS  PubMed  Google Scholar 

Busardò FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13:47–70.

Article  PubMed  PubMed Central  Google Scholar 

Abanades S, Farre M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006;1074:559–76.

Article  CAS  PubMed  Google Scholar 

Seiden D, Tyler C, Dubow J. Pharmacokinetics of FT218, a once-nightly sodium oxybate formulation in healthy adults. Clin Ther. 2021;43:672e1-e14.

United States Congress. H.R.2130—Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000. 2000. https://www.congress.gov/bill/106th-congress/house-bill/2130. Accessed 2024.

Gabay M. The federal controlled substances act: schedules and pharmacy registration. Hosp Pharm. 2013;48:473–4.

Article  PubMed  PubMed Central  Google Scholar 

Tunnicliff G, Raess BU. Gamma-hydroxybutyrate (orphan medical). Curr Opin Investig Drugs. 2002;3:278–83.

CAS  PubMed  Google Scholar 

US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25:42–9.

Google Scholar 

US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5:119–23.

Article  Google Scholar 

Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6:415–21.

Article  Google Scholar 

US Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26:31–5.

Google Scholar 

Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1:391–7.

Article  Google Scholar 

Jazz Pharmaceuticals. Xyrem® (sodium oxybate). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals, Inc; 2023.

Jazz Pharmaceuticals. Jazz Pharmaceuticals, Inc. Release: Xyrem® Receives FDA approval for the treatment of excessive daytime sleepiness in patients with narcolepsy. 2005.